Latest Financial Health News

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

LaserBond Limited reported a solid 10.4% rise in net profit for FY25, supported by steady revenue growth and a strategic equity stake in Gateway Group. The company also declared a fully franked final dividend, signaling confidence in future earnings.

Helia Group Limited has announced a combined ordinary and special dividend totaling AUD 0.43 per share, set for payment in mid-September 2025.

Babylon Pump & Power Limited reported a 24% revenue decline for FY2025 but achieved a 55% increase in profit, highlighting improved operational efficiency amid challenging conditions.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

GLG Corp has significantly revised its profit guidance for FY2025, now expecting a net loss of up to $1.5 million, a sharp increase from earlier estimates.

MaxiPARTS Limited reported a robust FY25 with revenues climbing 9.5% to $267.1 million and net profit soaring 179% to $7.7 million, underpinned by strategic acquisitions and margin improvements.

FFI Holdings Limited reported a remarkable 283.5% jump in net profit for FY2025, driven by property revaluations and operational growth, while raising $7.2 million to fund expansion in food manufacturing and property development.

NRW Holdings Limited has announced a fully franked ordinary dividend of AUD 0.095 per share for the six months ending June 30, 2025, signaling steady returns for shareholders.

Whitehaven Coal Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the six months ending June 2025, signaling steady returns for shareholders.

Qube Holdings Limited has announced a fully franked ordinary dividend of AUD 0.057 per share for the six months ending June 2025, signaling steady shareholder returns amid a stable operational period.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.